Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics.
Harshita TiwariNilesh RaiSwati SinghPriyamvada GuptaAshish VermaAkhilesh Kumar Singhnull KajalPrafull SalviSantosh Kumar SinghVibhav GautamPublished in: Bioengineering (Basel, Switzerland) (2023)
Nano-oncology is a branch of biomedical research and engineering that focuses on using nanotechnology in cancer diagnosis and treatment. Nanomaterials are extensively employed in the field of oncology because of their minute size and ultra-specificity. A wide range of nanocarriers, such as dendrimers, micelles, PEGylated liposomes, and polymeric nanoparticles are used to facilitate the efficient transport of anti-cancer drugs at the target tumor site. Real-time labeling and monitoring of cancer cells using quantum dots is essential for determining the level of therapy needed for treatment. The drug is targeted to the tumor site either by passive or active means. Passive targeting makes use of the tumor microenvironment and enhanced permeability and retention effect, while active targeting involves the use of ligand-coated nanoparticles. Nanotechnology is being used to diagnose the early stage of cancer by detecting cancer-specific biomarkers using tumor imaging. The implication of nanotechnology in cancer therapy employs photoinduced nanosensitizers, reverse multidrug resistance, and enabling efficient delivery of CRISPR/Cas9 and RNA molecules for therapeutic applications. However, despite recent advancements in nano-oncology, there is a need to delve deeper into the domain of designing and applying nanoparticles for improved cancer diagnostics.
Keyphrases
- cancer therapy
- drug delivery
- papillary thyroid
- early stage
- squamous cell
- crispr cas
- palliative care
- drug release
- quantum dots
- high resolution
- squamous cell carcinoma
- emergency department
- radiation therapy
- endothelial cells
- stem cells
- bone marrow
- genome editing
- combination therapy
- sentinel lymph node
- adverse drug
- smoking cessation
- rectal cancer